石药集团创新药大突破：降糖新复方、减重双靶点、降压新策略齐获临床批件

摩熵医药2025-12-31

12月29日晚，石药集团发布公告，其三大创新药物同步获得临床试验批件，覆盖糖尿病、减重、高血压三大热门治疗领域。其中，GLP-1/GIP双受体激动剂、全球首创三药联合复方降糖药、以及高选择性醛固酮抑制剂，均展现出强劲的临床开发潜力。截图来源：企业公告一、降糖新突破：全球首个三药复方制剂获批临床石药集团开发的普卢格列汀达格列净二甲双胍缓释片，成为全球首个获批临床的由普卢格列汀、达格列净和盐酸二甲双胍...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2600032637?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-12-31 11:22","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2600032637","market":"hk","top_or_hot":-1,"title":"石药集团创新药大突破：降糖新复方、减重双靶点、降压新策略齐获临床批件","media":"摩熵医药","content":"<div>\n<p>12月29日晚，石药集团发布公告，其三大创新药物同步获得临床试验批件，覆盖糖尿病、减重、高血压三大热门治疗领域。其中，GLP-1/GIP双受体激动剂、全球首创三药联合复方降糖药、以及高选择性醛固酮抑制剂，均展现出强劲的临床开发潜力。截图来源：企业公告一、降糖新突破：全球首个三药复方制剂获批临床石药集团开发的普卢格列汀达格列净二甲双胍缓释片，成为全球首个获批临床的由普卢格列汀、达格列净和盐酸二甲双胍...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251231112312a6e3b8f1&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>石药集团创新药大突破：降糖新复方、减重双靶点、降压新策略齐获临床批件</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n石药集团创新药大突破：降糖新复方、减重双靶点、降压新策略齐获临床批件\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-31 11:22 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251231112312a6e3b8f1&s=b><strong>摩熵医药</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>12月29日晚，石药集团发布公告，其三大创新药物同步获得临床试验批件，覆盖糖尿病、减重、高血压三大热门治疗领域。其中，GLP-1/GIP双受体激动剂、全球首创三药联合复方降糖药、以及高选择性醛固酮抑制剂，均展现出强劲的临床开发潜力。截图来源：企业公告一、降糖新突破：全球首个三药复方制剂获批临床石药集团开发的普卢格列汀达格列净二甲双胍缓释片，成为全球首个获批临床的由普卢格列汀、达格列净和盐酸二甲双胍...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251231112312a6e3b8f1&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999004220.SGD","symbol_name":"Nikko AM Shenton Asia Dividend Equity Fund  SGD","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251231112312a6e3b8f1&s=b","article_id":"2600032637","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251231112312a6e3b8f1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2600032637","pubTimestamp":1767151352,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"12月29日晚，石药集团发布公告，其三大创新药物同步获得临床试验批件，覆盖糖尿病、减重、高血压三大热门治疗领域。结语石药集团此次三大创新药同期获批临床，标志着其在代谢疾病和心血管疾病领域的研发实力已进入加速阶段。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"SG9999004220.SGD":"Nikko AM Shenton Asia Dividend Equity Fund  SGD","LU0314109678.HKD":"MANULIFE GF DRAGON GROWTH \"AA\" (HKD) INC","LU1008478684.HKD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (HKD) ACC","IE0008368742.USD":"首域中国增长基金I Acc","LU0072913022.USD":"UBS (LUX) EQUITY FUND -  GREATER CHINA \"P\" (USD) ACC","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","LU0326950275.SGD":"Schroder ISF China Opportunities A Acc SGD-H","IE00B031HY20.USD":"FSSA CHINA GROWTH \"I\" (USD) INC","LU1226288170.HKD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"P6%\"(HK D) INC","LU1226287529.USD":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) ACC","LU1226287875.USD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"PM\" (USD) INC","LU0880133367.SGD":"UBS (LUX) EQUITY FUND CHINA OPPORTUNITY USD \"P\" (SGD) ACC","BK1161":"生物科技","LU1226288253.USD":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) INC","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","BK1191":"制药","06978":"永泰生物-B","LU2039709279.SGD":"MANULIFE GF DRAGON GROWTH \"AA\" (SGDHDG) INC","LU1951186391.HKD":"UBS (LUX) KEY SEL CHINA ALLOCATION OPPORTUNITY (US \"P\" (HKD) INC","01093":"石药集团","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","LU1813983027.USD":"MANULIFE GF DRAGON GROWTH \"AA\" (USD) INC","IE0008369823.USD":"FSSA HONG KONG GROWTH \"I\" ACC","LU1152091168.USD":"UBS (LUX) EQUITY FUND - CHINA OPPORTUNITY (USD) \"PM\" INC","LU1807302812.USD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (USD) ACC","BK1515":"抗疫概念","LU1993786604.SGD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (SGD) ACC","LU1226287792.SGD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"P\" (SGDHDG) INC","BK1574":"生物医药B类股","LU1960683339.HKD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (HKD) ACC","LU0140636845.USD":"施罗德大中华区股票A Acc","IE00BZ08YR35.GBP":"GUINNESS BEST OF CHINA \"C\" (GBP) ACC","LU0067412154.USD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (USD) ACC","LU0315179316.USD":"EASTSPRING INVESTMENTS ASIAN DYNAMIC \"A\" (USD) ACC","LU0501845795.SGD":"瑞银大中华区股票基金P Acc SGD","LU1152091754.HKD":"UBS (LUX) EQUITY FUND - CHINA OPPORTUNITY (USD) \"PM\" (HKD) INC","IE00BZ08YS42.EUR":"GUINNESS BEST OF CHINA \"C\" (EUR) ACC","IE00BZ08YT58.USD":"GUINNESS BEST OF CHINA \"C\" (USD) ACC","LU1328277881.USD":"MANULIFE GF DRAGON GROWTH FUND \"AA\" (USD) INC","BK1521":"挪威政府全球养老基金持仓"},"translate_title":"CSPC's breakthrough in innovative drugs: new hypoglycemic compounds, dual targets for weight loss, and new strategies for hypotension have all obtained clinical approval","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06978":1.5,"01093":1.5},"content_text":"12月29日晚，石药集团发布公告，其三大创新药物同步获得临床试验批件，覆盖糖尿病、减重、高血压三大热门治疗领域。其中，GLP-1/GIP双受体激动剂、全球首创三药联合复方降糖药、以及高选择性醛固酮抑制剂，均展现出强劲的临床开发潜力。截图来源：企业公告一、降糖新突破：全球首个三药复方制剂获批临床石药集团开发的普卢格列汀达格列净二甲双胍缓释片，成为全球首个获批临床的由普卢格列汀、达格列净和盐酸二甲双胍组成的三药联合复方制剂。据摩熵医药数据库显示，该产品自2025年10月21日首次申报临床，于同年12月26日即获临床批件。查数据，找摩熵！图源：摩熵医药-全球药物研发数据库该产品针对\"单独使用盐酸二甲双胍血糖控制不佳的成人2型糖尿病\"患者，通过三种不同作用机制的药物协同，实现对糖尿病多重病理生理机制的全方位覆盖。在提供有效血糖控制的同时，其独特的缓释剂型可减少服药次数，简化治疗，有望显著提升患者用药依从性。二、减重新利器：GLP-1/GIP双靶点激动剂登场SYH2069注射液有望成为中国首款进入临床阶段的GLP-1/GIP受体双偏向性激动剂。与传统多肽药物不同，该产品能够选择性激活cAMP通路，显著减少β-arrestin募集，从而有效降低受体内吞及脱敏风险，在提升药效的同时延长作用时间。查数据，找摩熵！图源：摩熵医药-全球药物研发数据库临床前研究显示，在饮食诱导肥胖小鼠和非人灵长类动物模型中，SYH2069在减重及代谢改善方面表现优异，效果显著超越同类已上市产品。值得注意的是，在重复给药毒理研究中，该产品耐受性良好，未观察到呕吐及胃肠道不良反应，这为后续临床应用提供了重要安全性依据。三、高血压新策略：精准抑制醛固酮合成SYH2072片作为高选择性强效醛固酮合成酶抑制剂，能够精准降低血浆醛固酮水平，且不影响皮质醇分泌。临床前数据显示，该产品在高血压动物模型中表现出剂量依赖性降压效果，同时维持良好的药代动力学特征和安全性。查数据，找摩熵！图源：摩熵医药-全球药物研发数据库该产品将针对未控制高血压和原发性醛固酮增多症开展临床研究。其高选择性机制使其具备成为best-in-class药物的潜力，目前已在国内外提交多项专利申请，展现出石药在该领域的全面布局。结语石药集团此次三大创新药同期获批临床，标志着其在代谢疾病和心血管疾病领域的研发实力已进入加速阶段。从全球首创的三药复方制剂，到具有差异化优势的GLP-1/GIP双靶点激动剂，再到精准的高选择性醛固酮抑制剂，石药正通过多元化的创新策略，在多个高价值治疗领域构建具有国际竞争力的产品管线。石药集团全球新药研发阶段分布可直接点击跳转到数据库免费查看最新数据详细信息随着中国创新药研发能力的持续提升，以石药为代表的国内药企，正在从fast-follow向first-in-class/best-in-class战略转型。这不仅是企业自身研发实力的体现，更为中国患者带来了更多与国际同步的创新治疗选择。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2600032637","isCrawlerRequest":true}